热休克蛋白90在乳腺癌发生发展及治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2022.04.017

Abstract

Abstract: Breast cancer has become one of the malignant tumors highest incidence.Heat shock protein 90(HSP90)is called a molecular chaperone,which plays an important role in the synthesis of peptide,control of protein quantity,protein folding,activity and degradation.HSP90 can regulate cell growth,adhesion,invasion,metastasis,angiogenesis and apoptosis,etc,and plays an important role in the development of breast cancer.HSP90 inhibitors play an active role in resisting tumor growth and inhibiting invasion,becoming a new treatment method.This article further elucidates the relationship between HSP90 and breast cancer,and the new mode of breast cancer treatment mediated by HSP90 inhibitors.

Key words: Breast cancer, Heat shock protein 90, Heat shock protein 90 inhibitor

CLC Number:

R737.9

ZONG Yuxuan, PANG Da. Research progress of heat shock protein 90 in the occurrence,development and treatment of breast cancer[J]. Journal of Practical Oncology, 2022, 36(4): 381-385.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.04.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I4/381

References

1 Zeng L,Li W,Chen CS.Breast cancer animal models and applications[J].Zool Res,2020,41(5):477-494.
2 Barzaman K,Karami J,Zarei Z.Breast cancer:biology,biomarkers,and treatments[J].Int Immunopharmacol,2020,84:106535.
3 Graner MW.HSP90 and immune modulation in cancer[J].Adv Cancer Res,2016,29:191-224.
4 Barna J,Csermely P,Vellai T.Roles of heat shock factor 1 beyond the heat shock response[J].Cell Mol Life Sci,2018,75(16):2897-2916.
5 Pearl LH,Prodromou C.Structure and mechanism of the Hsp90 molecular chaperone machinery[J].Annu Rev Biochem,2006,75:271-294.
6 Kampinga HH,Hageman J,Vos MJ,et al.Guidelines for the nomenclature of the human heat shock proteins[J].Cell Stress Chaperones,2009,14(1):105-111.
7 Dzaman-Serafin S.Heat shock proteins and their characteristics[J].Pol Merkur Lekarski,2005,19(110):215-219.
8 Schopf FH,Biebl MM,Buchner J.The HSP90 chaperone machinery[J].Nat Rev Mol Cell Biol,2017,18(6):345-360.
9 Li T,Kang G,Wang T,et al.Tumor angiogenesis and anti-angiogenic gene therapy for cancer[J].Oncol Lett,2018,16(1):687-702.
10 Zhang PC,Liu X,Li MM.AT-533,a novel Hsp90 inhibitor,inhibits breast cancer growth and HIF-1/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo[J].Biochem Pharmacol,2020,172:113771.
11 Jafari A,Rezaei-Tavirani M,Farhadihosseinabadi B,el at.HSP90 and Co-chaperones:impact on tumor progression and prospects for molecular-targeted cancer therapy[J].Cancer Invest,2020,38(5):310-328.
12 Bai J,Zhou G,Qiu Y,et al.HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells[J].Cancer Sci,2017,108(6):1177-1184.
13 Calderwood SK,Gong J.Heat shock proteins promote cancer:it's a protection racket[J].Trends Biochem Sci,2016,41(4):311-323.
14 Costa TEMM,Raghavendra NM,Penido C,et al.Natural heat shock protein 90 inhibitors in cancer and inflammation[J].Eur J Med Chem,2020,189:112063.
15 Cheng Q,Chang JT,Geradts J,et al.Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer[J].Breast Cancer Res,2012,14(2):62.
16 Barrott JJ,Haystead TA.Hsp90.an unlikely ally in the war on cancer[J].FEBS J,2013,280(6):1381-1396.
17 Crouch BT,Gallagher J,Wang R,et al.Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer[J].Sci Rep,2019,9(1):3461.
18 Gao C,Peng YN,Wang HZ,et al.Inhibition of heat shock protein 90 as a novel platform for the treatment of cancer[J].Curr Pharm Des,2019,25(8):849-855.
19 García-Becerra R,Santos N,Díaz L,et al.Mechanisms of resistance to endocrine therapy in breast cancer:focus on signaling pathways,miRNAs and genetically based resistance[J].Int J Mol Sci,2012,14(1):108-145.
20 Schiff R,Massarweh S,Shou J,et al.Breast cancer endocrine resistance:how growth factor signaling and estrogen receptor coregulators modulate response[J].Clin Cancer Res,2003,9(1 Pt 2):447-454.
21 Krämer OH,Mahboobi S,Sellmer A,et al.Drugging the HDAC6-HSP90 interplay in malignant cells[J].Trends Pharmacol Sci,2014,35(10):501-509.
22 Bali P,Pranpat M,Bradner J,et al.Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90:a novel basis for antileukemia activity of histone deacetylase inhibitors[J].J Biol Chem,2005,280(29):26729-26734.
23 Robinson DR,Wu YM,Vats P,et al.Activating ESR1 mutationsinhormone-resistant metastatic breast cancer[J].Nat Genet,2013,45(12):1446-1451.
24 Ring A,Dowsett M.Mechanisms of tamoxifen resistance[J].Endocr Relat Cancer,2004,11(4):643-658.
25 Genest O,Wickner S,Doyle SM,et al.Hsp90 and Hsp70 chaperones:Collaborators in protein remodeling[J].J Biol Chem,2019,294(6):2109-2120.
26 Meng QW,Zhao CH,Xi YH,et al.Enhancement of HER-2 degradation by carbamazepine in breast cancer SKBR-3 cell line[J].Zhonghua Zhong Liu Za Zhi,2006,28(7):503-506.
27 Modi S,Stopeck AT,Gordon MS,et al.Combination of trastuzumab and tanespimycin(17-AAG,KOS-953)is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer:a phase I dose-escalation study[J].J Clin Oncol,2007,25(34):5410-5417.
28 Talaei S,Mellatyar H,Asadi A,et al.Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment[J].Chem Biol Drug Des,2019,93(5):760-786.
29 Canonici A,Qadir Z,Conlon NT,et al.The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells[J].Invest New Drugs,2018,36(4):581-589.
30 Nash K,Hafeez A,Hou S.Hospital-acquired renal insufficiency[J].Am J Kidney Dis,2002,9(5):930-936.
31 Cho TM,Kim JY,Kim YJ,et al.C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition[J].Cancer Lett,2019,447:141-153.
32 Li L,Wang L,You QD,et al.Heat shock protein 90 inhibitors:an update on achievements,challenges,and future directions[J].J Med Chem,2020,63(5):1798-1822.
33 Garg G,Khandelwal A,Blagg BS,et al.Anticancer inhibitors of Hsp90 function:beyond the usual suspects[J].Adv Cancer Res,2016,129:51-88.

[1]	CHEN Jiayi, BAI Yanling. The influence of body mass index and body position fixation in breast cancer patients post-operative intensity modulated radiation therapy setup error [J]. Journal of Practical Oncology, 2022, 36(4): 327-331.
[2]	ZHAO Danni, YAN Shi, CAI Li. Research progress on follow - up and drug side effect management strategy of breast cancer [J]. Journal of Practical Oncology, 2022, 36(4): 369-373.
[3]	YANG Zihan, XU Shouping, PANG Da. Characteristics of breast cancer metastases to outer triangle tissue and its influencing factors [J]. Journal of Practical Oncology, 2022, 36(3): 226-232.
[4]	HE Weidan, LI Zhigao. FSIP1 promotes migration and invasion of breast cancer cells and leads to poor prognosis of patients [J]. Journal of Practical Oncology, 2022, 36(3): 233-238.
[5]	LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment [J]. Journal of Practical Oncology, 2022, 36(3): 250-254.
[6]	YANG Shuya, LIU Wenhui, LUO Naixiang. Research status and application prospect of UCA1 in breast cancer [J]. Journal of Practical Oncology, 2022, 36(3): 263-267.
[7]	LIU Wanying, PANG Da. Research progress on the mechanism of metastasis in invasive micropapillary carcinoma of the breast [J]. Journal of Practical Oncology, 2022, 36(3): 268-272.
[8]	SUN Yuanyuan, ZHANG Ningzhi, CAO Mengru. The mechanism and treatment progress of breast cancer lung metastasis [J]. Journal of Practical Oncology, 2022, 36(2): 173-177.
[9]	HOU Jianxun, WANG Hongbin. Research progress on the influence of exosomes in the integration of breast cancer diagnosis and treatment [J]. Journal of Practical Oncology, 2022, 36(2): 178-182.
[10]	CHEN He, WANG Qiucheng, CHENG Wen. The application progress of automatic breast ultrasound diagnosis system in breast cancer [J]. Journal of Practical Oncology, 2022, 36(2): 193-196.
[11]	LI Weihua, ZHANG Guangfeng, MA Lili, HE Pin, WANG Wen, LI Dingfu. Construction of a breast cancer prognostic model based on metabolism-related genes in the TCGA database [J]. Journal of Practical Oncology, 2022, 36(1): 37-43.
[12]	CAO Shiyu, JIANG Yongdong. The influence of gene expression,polygene detection and biomarkers on the prognosis of Luminal A-like breast cancer [J]. Journal of Practical Oncology, 2022, 36(1): 89-93.
[13]	LUO Bo, ZHANG Qu, ZHENG Hongmei, LIANG Xinjun, ZHOU Xiaomei, WU Xinhong. Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis [J]. Journal of Practical Oncology, 2021, 35(6): 523-528.
[14]	SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer [J]. Journal of Practical Oncology, 2021, 35(6): 529-533.
[15]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.

Research progress of heat shock protein 90 in the occurrence,development and treatment of breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments